Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study
Health Science Reports · 2026-03 · 9 (3)
DOI: 10.1002/hsr2.72142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 22.03.2026. Verfasst von Majid Jafari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Development Unit, Kashani Hospital Shahrekord University of Medical Sciences Shahrekord Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multiple sclerosis (MS) is the most prevalent immune‐mediated neurodegenerative disease affecting the central nervous system. Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, has demonstrated significant efficacy in reducing disease activity and improving clinical outcomes of people with MS (PwMS) in clinical trials. However, real‐world data are crucial for assessing the efficacy and safety of ocrelizumab. Thus, the current study aimed to evaluate the long‐term clinical and psychological efficacy and safety profile of ocrelizumab in PwMS compared with other disease‐modifying therapies (DMTs).
Methods
This longitudinal study was carried out between January 2022 and February 2024 in Isfahan, Iran. 51 PwMS were included, of whom 21 patients were DMT‐naïve, while 30 patients were on other DMTs, including interferon‐β, fingolimod, dimethyl fumarate, natalizumab, or teriflunomide. Demographic characteristics, clinical outcomes, including Expanded Disability Status Scale (EDSS), annualized relapse rate (ARR), timed 25‐foot walk (T25FW) test, and nine‐hole peg test (9‐HPT), as well as psychological measures including anxiety, depression, and fatigue, were evaluated at baseline (T0), and 12 months (T1) and 24 months (T2) of follow‐up. Adverse events (AEs) were obtained using chart review and patient self‐reports in clinical visits.
Results
ARR was significantly decreased at T1 (Z = −5.4, p < 0.001) and T2 (Z = −4.03, p < 0.001) in PwMS who received ocrelizumab. Similarly, a significant decrease was found in 9‐HPT (Z = −5.16, p < 0.001) and T25FW (Cohen's d = −0.72, p < 0.001) at T1. Depression and fatigue significantly improved at T1 (Z = −3.89, p < 0.001, Cohen's d = −1.16, p < 0.001, respectively) and further at T2 (Z = −2.18, p = 0.029, Cohen's d = −1.59, p < 0.001, respectively), and anxiety at T1 (Z = −3, p = 0.003). PwMS who initiated ocrelizumab as a first‐line therapy showed a significantly greater reduction in ARR, 9‐HPT, and T25FW than those previously treated with other DMTs (all p < 0.05), while no significant differences were observed in terms of changing EDSS, anxiety, depression, or fatigue levels. Respiratory infections (13.7%), infusion‐related reactions (5.9%), and headache (5.9%) were the most frequent AEs, and no serious infection was observed.
Conclusion
Ocrelizumab may reduce disease activity and improve functional and psychological outcomes in PwMS, while maintaining a favorable safety profile. Moreover, relapse rates and functional impairment were improved more in groups that initiated ocrelizumab as a first‐line therapy than in other disease‐modifying therapies. These findings suggest that ocrelizumab is a promising first‐line treatment in MS. However, further studies are needed to confirm these preliminary results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Research Development Unit, Kashani Hospital Shahrekord University of Medical Sciences Shahrekord Iran.
- Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran.
- Department of Neurology Isfahan University of Medical Sciences Isfahan Iran.
- Department of Neurology University of Cincinnati Cincinnati OH USA.
ORCID-Profile: Mohammad Yazdan Panah, Saeed Vaheb, Iman Adibi, Fereshteh Ashtari, Vahid Shaygannejad, Omid Mirmosayyeb
Zitieren
APA
Jafari, M., Yazdan Panah, M., Vaheb, S., Adibi, I., Ashtari, F., Shaygannejad, V., Zabeti, A., & Mirmosayyeb, O. (2026). Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study. Health Science Reports, 9(3). https://doi.org/10.1002/hsr2.72142
Vancouver
Jafari M, Yazdan Panah M, Vaheb S, Adibi I, Ashtari F, Shaygannejad V, et al. Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study. Health Science Reports. 2026;9(3). doi:10.1002/hsr2.72142
BibTeX
@article{Jafari2026,
author = {Jafari, Majid and Yazdan Panah, Mohammad and Vaheb, Saeed and Adibi, Iman and Ashtari, Fereshteh and Shaygannejad, Vahid and Zabeti, Aram and Mirmosayyeb, Omid},
title = {Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {3},
doi = {10.1002/hsr2.72142}
}
EUVIMED